Clinical trials: Schizophrenia
Schizophrenia
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
The primary purpose of this study to evaluate the effect of a supratherapeutic dose of 80 mg elpipodect on the QT interval corrected for heart rate (QTc interval) and to assess the safety and tolerability of multiple once-daily…
- Trial name
- TQT (NCT05893862)
- Testing
- Elpipodect, Moxifloxacin
- Where
- 4 sites in United States
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Schizoaffective Disorder
Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the maintenance of antipsychotic efficacy and safety of risperidone long-acting injectable (RLAI) in patients with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01888107
- Testing
- Risperidone Long-acting Injectable (LAI) 25 mg, Risperidone LAI 37.5 mg, Risperidone LAI 50 mg
- Volunteers
- 347 people
- Sponsor
- Janssen-Cilag S.p.A.
Schizophrenia
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.
- Trial name
- NCT06136936
- Testing
- CT-156-C-001
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.
- Trial name
- NCT00418171
- Testing
- Ziprasidone, Olanzapine
- Where
- 5 sites in United States
- Volunteers
- 18,239 people
- Sponsor
- Pfizer
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
This study is being conducted to evaluate the safety and tolerability of ascending multiple oral doses of SCA-136 adminstered to healthy Japanese and non-Japanese female subjects.
- Trial name
- NCT00458107
- Testing
- SCA-136
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in…
- Trial name
- NCT02220712
- Testing
- OPC-14597 IMD
- Where
- 5 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
To determine the pharmacokinetics, safety and tolerability of brexpiprazole administered subcutaneously or intramuscularly in adults with schizophrenia.
- Trial name
- NCT02968121
- Testing
- Brexpiprazole, OPDC-34712
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute…
- Trial name
- NCT07734493
- Testing
- LTX-001 once daily, LTX-001 twice daily
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Leal Therapeutics, Inc
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192906
- Testing
- bitopertin [RO4917838]
- Where
- 113 sites in United States, Brazil and 12 more
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
A clinical trial study to determine the effect of an investigational drug (SEP-363856) has on the way that the drug Metformin travels through the body in people with schizophrenia.
- Trial name
- NCT04865835
- Testing
- SEP-363856, metformin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Acute Episode
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control.
- Trial name
- NCT03055338
- Testing
- Elpipodect, Risperidone
- Where
- 28 sites in United States
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Bipolar Disorder
A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder
The purposes of this study are to evaluate the effects of a potent metabolic enzyme inducer, carbamazepine, on the steady-state pharmacokinetics of orally administered paliperidone ER and to evaluate the safety and tolerability…
- Trial name
- NCT00892125
- Testing
- paliperidone ER; Carbamazepine
- Volunteers
- 64 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder, Schizophrenia
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
This is a two-part trial. The primary objective of Part A is to estimate the ratio of geometric means of pharmacokinetic (PK) parameters and their within-subject variability for the 300mg quetiapine tablet formulation A and the…
- Trial name
- NCT03872596
- Testing
- Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia, Alzheimer Disease
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
- Conditions
- Dementia, Alzheimer Disease, Mental Disorders
- Trial name
- NCT00034762
- Testing
- risperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
The purpose of this study is to assess the safety, tolerability and PK profile of a single dose of 60mg RBO-7000 in stable subjects with schizophrenia who are on medication other than risperidone.
- Trial name
- NCT02765555
- Testing
- RBP-7000
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indivior Inc.
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.
- Trial name
- ERUDITE (NCT05182476)
- Testing
- Luvadaxistat
- Where
- 49 sites in United States, Bulgaria and 3 more
- Volunteers
- 216 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Parkinson's Disease, Psychotic Disorders
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease.
- Trial name
- NCT00125138
- Testing
- Melperone HCl
- Where
- 21 sites in United States, India and 1 more
- Volunteers
- 90 people
- Sponsor
- Lundbeck LLC
Schizophrenia
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
- Trial name
- NCT00083668
- Testing
- Paliperidone ER
- Volunteers
- 619 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters.
- Trial name
- NCT05563818
- Testing
- WinterLight Mobile Phone Speech Analysis
- Where
- 4 sites in Algeria, Egypt and 2 more
- Volunteers
- 57 people
- Sponsor
- Hikma Pharmaceuticals LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.